This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DOWSETT, M. Articles by JEFFCOATE, S.L. Search for Related Content PubMed PubMed Citation Articles by DOWSETT, M. Articles by JEFFCOATE, S.L.

Endocrine Changes Associated with Relapse in Advanced Breast Cancer Patients on Aminoglutethimide Therapy

Endocrine Department, Chelsea Hospital for Women London SW3 6LT
Department of Radiotherapy and Clinical Oncology, Newcastle General Hospital Newcastle upon Tyne NE4 6BE
Breast Unit, Royal Marsden Hospital London SW3 6JJ, United Kingdom

Address all correspondence and requests for reprints to: M. Dowsett, Endocrine Department, Chelsea Hospital for Women, Dovehouse Street, London SW3 6LT, United Kingdom.

About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs. In this study, 36 patients who initially responded to this treatment were evaluated to determine whether clinical relapse was associated with escape from endocrine suppression. Plasma estrone levels rose significantly (mean increase, 6.8 pg/ml) during the final 15 of time on treatment before relapse. Mean plasma estradiol, dehydroepiandosterone sulfate, and androstenedione levels also rose with the approach of the relapse, but the increases were not statistically significant. The increase in estrone may contribute to the progression of disease.

Received April 18, 1983.

This article has been cited by other articles:

				W. R. Miller, J. Bartlett, A. M. H. Brodie, R. W. Brueggemeier, E. di Salle, P. E. Lonning, A. Llombart, N. Maass, T. Maudelonde, H. Sasano, et al. Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter? Oncologist, August 1, 2008; 13(8): 829 - 837. [Abstract] [Full Text] [PDF]

				J. Geisler, B. Haynes, G. Anker, M. Dowsett, and P. E. Lonning Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study J. Clin. Oncol., February 1, 2002; 20(3): 751 - 757. [Abstract] [Full Text] [PDF]